ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Triethylamine → 1-{1-[6-(4-Nitro-2,3-dihydroindole-1-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydroimidazo[4,5-b]pyridin-2-one

HRID 74529
印刷

反応式

HRID 74529 の反応式
CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.[O:23]=[C:24]1[NH:32][C:27]2=[N:28][CH:29]=[CH:30][CH:31]=[C:26]2[N:25]1[CH:33]1[CH2:38][CH2:37][N:36]([C:39]2[N:44]=[CH:43][N:42]=[C:41]([C:45](O)=[O:46])[CH:40]=2)[CH2:35][CH2:34]1.[N+:48]([C:51]1[CH:59]=[CH:58][CH:57]=[C:56]2[C:52]=1[CH2:53][CH2:54][NH:55]2)([O-:50])=[O:49].C(N(CC)CC)C>CN(C=O)C.O>[N+:48]([C:51]1[CH:59]=[CH:58][CH:57]=[C:56]2[C:52]=1[CH2:53][CH2:54][N:55]2[C:45]([C:41]1[N:42]=[CH:43][N:44]=[C:39]([N:36]2[CH2:37][CH2:38][CH:33]([N:25]3[C:26]4[C:27](=[N:28][CH:29]=[CH:30][CH:31]=4)[NH:32][C:24]3=[O:23])[CH2:34][CH2:35]2)[CH:40]=1)=[O:46])([O-:50])=[O:49]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 4

HCID 8471TriethylamineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 132366324-Nitro-2,3-dihydro-1H-indoleHCID 583866966-[4-(2-Oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]pyrimidine-4-carboxylic acid

生成物 1

HCID 583863791-{1-[6-(4-Nitro-2,3-dihydroindole-1-carbonyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydroimidazo[4,5-b]pyridin-2-one

試薬・触媒・溶媒 2

HCID 962Water溶媒HCID 6228Dimethylformamide溶媒

実験手順

150 mg (0.470 mmol) TBTU were added to 150 mg (0.44 mmol) 6-[4-(2-oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid, 75 mg (0.46 mmol) 4-nitro-2,3-dihydro-1H-indole, 100 μL (0.712 mmol) triethylamine in 1.5 mL DMF and the mixture was stirred overnight at RT. The reaction mixture was poured onto 30 mL water. The aqueous phase was extracted with DCM (3×20 mL). The combined organic phases were dried on magnesium sulphate, filtered and evaporated down i. vac. The residue was dissolved in 3 mL DMF, filtered through a syringe filter and purified by preparative HPLC. The product fractions were combined and lyophilised.

後処理

  1. extractionThe aqueous phase was extracted with DCM (3×20 mL)
  2. customThe combined organic phases were dried on magnesium sulphate
  3. filtrationfiltered
  4. customevaporated down i
  5. dissolutionThe residue was dissolved in 3 mL DMF
  6. filtrationfiltered through a syringe
  7. filtrationfilter
  8. custompurified by preparative HPLC

出典と根拠

ORDレコード
ord-cd8e6db8c4a94aeaa3ad584dd44fa0b7
出典データセット
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08829006B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート